In Vivo Evaluation of Antiviral Compounds on Respiratory Syncytial Virus Using a Juvenile Vervet Monkey (Chlorocebus pygerythrus) Infection Model

Part of the Methods in Molecular Biology book series (MIMB, volume 1030)


Several animal models with varying susceptibilities to respiratory syncytial virus (RSV) infection have been developed to study the specific aspects of RSV disease. Many of these models are used for testing antiviral compounds or in vaccine efficacy studies during preclinical evaluation. In this chapter, we describe the study design of an efficacy study of an RSV inhibitor, performed in a juvenile vervet monkey model for RSV.

Key words

Respiratory syncytial virus Monkey model RSV inhibitor Animal infection model 



This research was supported in part by a grant of the Institute for the Promotion of Innovation by Science and Technology in Flanders (IWT), project number 070005. Piet Maes is supported by a postdoctoral grant from the “Fonds voor Wetenschappelijk Onderzoek (FWO)-Vlaanderen”. We gratefully acknowledge Dr. Thomas Karuiki and the staff at the Institute of Primate Research, Nairobi, Kenya for the excellent technical assistance. We would also like to thank our colleagues of the Laboratory of Clinical Virology and R&D of Janssen Infectious Diseases for their contribution to the study design and review of the manuscript.


  1. 1.
    Bem RA, Domachowske JB, Rosenberg HF (2011) Animal models of human respiratory syncytial virus disease. Am J Physiol Lung Cell Mol Physiol 301:148–156CrossRefGoogle Scholar
  2. 2.
    Kong X, Hellermann GR, Patton G et al (2005) An immunocompromised BALB/c mouse model for respiratory syncytial virus infection. Virol J 2:3PubMedCrossRefGoogle Scholar
  3. 3.
    Boukhvalova MS, Prince GA, Blanco JC (2009) The cotton rat model of respiratory viral infections. Biologicals 37:152–159PubMedCrossRefGoogle Scholar
  4. 4.
    Prince GA, Suffin SC, Prevar DA et al (1979) Respiratory syncytial virus infection in owl monkeys: viral shedding, immunological response, and associated illness caused by wild-­type virus and two temperature-sensitive mutants. Infect Immun 26:1009–1013PubMedGoogle Scholar
  5. 5.
    Belshe RB, Richardson LS, London WT et al (1977) Experimental respiratory syncytial virus infection of four species of primates. J Med Virol 1:157–162PubMedCrossRefGoogle Scholar
  6. 6.
    Olivier A, Gallup J, de Macedo MM et al (2009) Human respiratory syncytial virus A2 strain replicates and induces innate immune responses by respiratory epithelia of neonatal lambs. Int J Exp Pathol 90:431–438PubMedCrossRefGoogle Scholar
  7. 7.
    Grieves JL, Jurcisek JA, Quist B et al (2010) Mapping the anatomy of respiratory syncytial virus infection of the upper airways in chinchillas (Chinchilla lanigera). Comp Med 60:225–232PubMedGoogle Scholar
  8. 8.
    Byrd LG, Prince GA (1997) Animal models of respiratory syncytial virus infection. Clin Infect Dis 25:1363–1368PubMedCrossRefGoogle Scholar
  9. 9.
    Bonfanti JF, Meyer C, Doublet F et al (2008) Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J Med Chem 51:875–896PubMedCrossRefGoogle Scholar
  10. 10.
    Houspie L, Ipsas G, Keyaerts E et al (2013) Juvenile vervet monkey model for human respiratory syncytial virus infection (manuscript in preparation)Google Scholar
  11. 11.
    Graham BS (2011) Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 239:149–166PubMedCrossRefGoogle Scholar
  12. 12.
    Jin H, Cheng X, Traina-Dorge VL et al (2003) Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Vaccine 21:3647–3652PubMedCrossRefGoogle Scholar
  13. 13.
    Kakuk TJ, Soike K, Brideau RJ et al (1993) A human respiratory syncytial virus (RSV) ­primate model of enhanced pulmonary pathology induced with a formalin-inactivated RSV vaccine but not a recombinant FG subunit vaccine. J Infect Dis 167:553–561PubMedCrossRefGoogle Scholar
  14. 14.
    Weiss WJ, Murphy T, Lynch ME et al (2003) Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J Med Primatol 32:82–88PubMedCrossRefGoogle Scholar
  15. 15.
    Huntley CC, Weiss WJ, Gazumyan A et al (2002) RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob Agents Chemother 46:841–847PubMedCrossRefGoogle Scholar
  16. 16.
    Olszewska W, Ispas G, Schnoeller C et al (2011) Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model. Eur Respir J 38:401–408PubMedCrossRefGoogle Scholar
  17. 17.
    Houspie L, Keyaerts E, Maes P et al (2012) Susceptibility of the PER.C6 cell line for infection with clinical human respiratory syncytial virus isolates. J Virol Methods 181:37–42PubMedCrossRefGoogle Scholar
  18. 18.
    Kagira JM, Ngotho M, Thuita JK et al (2007) Hematological changes in vervet monkeys (Chlorocebus aethiops) during eight months’ adaptation to captivity. Am J Primatol 69:1053–1063PubMedCrossRefGoogle Scholar
  19. 19.
    Ooi LS, Ho WS, Ngai KL et al (2010) Narcissus tazetta lectin shows strong inhibitory effects against respiratory syncytial virus, influenza A (H1N1, H3N2, H5N1) and B viruses. J Biosci 35:95–103PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  1. 1.Rega Institute for Medical ResearchUniversity of LeuvenLeuvenBelgium
  2. 2.Institute of Primate ResearchNairobiKenya
  3. 3.Janssen Infectious Diseases-Diagnostics BVBA, Johnson & Johnson CorporationBeerseBelgium

Personalised recommendations